Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-11-08
2005-11-08
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S501000, C540S568000
Reexamination Certificate
active
06962912
ABSTRACT:
The invention relates to novel substituted pyrazolo[4,3-e]-diazepines of general formula:to pharmaceutical compositions containing them, to their use as medicinal products and to processes for preparing them.
REFERENCES:
patent: 3764688 (1973-10-01), Swett et al.
Goel et al. (Synthesisf (1987), (2), 162-164). Abstract.
Baraldi, Pier, et. al., “Synthesis and Interaction of 5-(Substituted-phenyl)-3-methyl-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8(7H)-ones with Benzodiazepine Receptors in Rat Cerebral Cortex” Journal of Medicinal Chemistry vol. 28, No. 5, 1985 pp 683-685.
Beavo, Joseph A. et. al. “Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors,” Trends Pharmacol. Sci., vol. 11, 1990, pp. 150-155.
Beavo, Joseph A., “Multiple Cyclic Nucleotide Phosphodiesterases,” Molecular Pharmacology, 1994, pp. 399-405.
Chen, Yan-Lian, et. al., “Anti-tumor necrosis factor properties of non-peptide drugs in acute-phase responses,” European Journal of Pharmacology, vol. 271, 1994, pp. 319-327.
Prabhakar, Uma, et. al., Characterization of cAMP-Dependent Inhibition of LPS-induced TNFα Production by Rolipram, A Specific Phosphodiesterase IV (PDE IV) Inhibitor, Int. J. Immunopharmac., vol. 16, No. 10, 1994, pp. 805-816.
Corrigan, C.J., et. al., “T cells and eosinophils in the pathogenesis of asthma,” Immunology Today, vol. 13, No. 12, 1992, pp. 501-507.
Elwood, W., et al., “Inhibition of allergen-induced lung eosinophilla by type III and combined type III- and IV-selective Phosphodiesterase inhibitors in Brown-Norway Rats,” Inflamm Res. vol. 44, 1995, pp. 83-86.
Suter, Peter M., et. al., “High Bronchoalveolar Levels of Tumor Necrosis Factor and Its Inhibitors, Interleukin-1, Interferon, and Elastase, in Patients with Adult Respiratory Distress Syndrome after Trauma, Shock, or Sepsis,” Am. Rev. Respir. Dis., vol. 145, 1992, pp. 1016-1022.
Martin, Thomas R., et. al., “The Role of Chemokines in the Pathophysiology of the Acute Respiratory Distress Syndrome (ARDS),” Chemokines in Disease: Biology and Clinical Research, Chapter 6, 1999, pp. 81-110.
Repine, John E., et. al., “Neutrophils and Adult Respiratory Distress Syndrome: Two Interlocking Perspectives in 1991,” Am. Rev. Respir. Dis., vol. 144, 1991, pp. 251-252.
Cardelus, Ignasi, et. al., “Inhibition of lipopolysaccharide-induced bowel erythrocyte extravasation in rats, and of mesenteric hypoperfusion in dogs, by phosphodiesterase inhibitors,” European Journal of Pharmacology, vol. 299, 1996, pp. 153-159.
Berecibar Amaya
Burnouf Catherine
Navet Michael
Benson Gregg C.
Kifle Bruck
Richardson Peter C.
Ronau Robert T.
Warner-Lambert LLC
LandOfFree
Substituted pyrazolo[4,3-e]diazepines, pharmaceutical... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted pyrazolo[4,3-e]diazepines, pharmaceutical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted pyrazolo[4,3-e]diazepines, pharmaceutical... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3483582